In vivo studies show that YTHDF1 siRNA delivered via nanoliposomes significantly suppresses HCC growth and enhances the efficacy of sorafenib and Lenvatinib [8]. This evidence concerns the gene YTHDF1 and hepatocellular carcinoma.